glp 1 approved for nash Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression Akero's NASH therapy, paired with

Raben A, Andersen HB, Christensen NJ, Madsen J, Holst JJ, Astrup A

Fact: Most people with a history of the condition can take them, provided they are not in an active flare and have a plan to manage constipation

### Step 8: Label and Refrigerate Immediately write on the vial: - Reconstitution date - Concentration (e.g., "5mg/mL") - Use-by date (28 days from today) Place in the refrigerator within 5 minutes of reconstitution

In vivo studies with long-acting glucagon analogue suggest that hypoaminoacidaemia could be an important contributing mechanism to the observed increase in energy expenditure with glucagon agonism, but it also leads to enhanced lean mass loss [63]

It is believed that GLP-1RAs induce vasodilation through action of the proximal tubular cells and stimulating urinary sodium excretion [68, 72]